Capital Impact Advisors, LLC Eagle Pharmaceuticals, Inc. Put Options Transaction History
Capital Impact Advisors, LLC
- $3.16 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding EGRX
# of Institutions
46Shares Held
4.75MCall Options Held
1MPut Options Held
100-
Nantahala Capital Management, LLC New Canaan, CT2.36MShares$2.78 Million0.52% of portfolio
-
Aqr Capital Management LLC Greenwich, CT375KShares$442,4900.0% of portfolio
-
Black Rock Inc. New York, NY353KShares$416,2590.0% of portfolio
-
Morgan Stanley New York, NY192KShares$226,8110.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny185KShares$218,3680.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $15.4M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...